Myeloid Therapeutics presents late-breaking data on multiple platforms at the American Association for Cancer Research 2023 Annual Meeting April 18, 2023 Categories: Health Care Tags: Myeloid Therapeutics
Mythic Therapeutics announces first subject dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for the Treatment of Non-Small Cell Lung Cancer (NSCLC) April 6, 2023 Categories: Health Care Tags: Myeloid Therapeutics
Myeloid Therapeutics goes down under for new manufacturing site, with $66M local investment February 22, 2023 Categories: Health Care Tags: Myeloid Therapeutics
Myeloid Therapeutics: FDA grants fast track designation to CAR monocyte therapy for peripheral T-cell lymphoma November 3, 2022 Categories: Health Care Tags: Myeloid Therapeutics
Myeloid Therapeutics announces FDA fast track designation for MT-101 for the treatment of CD5+ Relapsed/Refractory PTCL October 28, 2022 Categories: Health Care Tags: Myeloid Therapeutics
Myeloid Therapeutics strengthens senior team to support the expansion of its manufacturing capabilities August 29, 2022 Categories: Health Care Tags: Myeloid Therapeutics
Myeloid Therapeutics CEO named one of the winners of the 2021 Emerging Pharma Leaders Awards May 11, 2021 Categories: Health Care Tags: Myeloid Therapeutics
Myeloid Therapeutics New: With lessons learned from Vor, Siddhartha Mukherjee takes a different route to target solid tumors with startup Myeloid January 6, 2021 Categories: Uncategorized Tags: Myeloid Therapeutics
Myeloid Therapeutics News: Myeloid Therapeutics launches with Over $50 million in financing and two clinical trials January 6, 2021 Categories: Uncategorized Tags: Myeloid Therapeutics
